|
Countermeasures Against Chemical Threats program (CounterACT)
|
Research Initiative
|
ASPR
|
NIEHS, NIAID, NIAMS, NICHD, NEI, NINDS, NIDA
|
The overarching goal of the CounterACT program is to integrate cutting-edge research with the latest technological advances in science and medicine for a more rapid and effective response during these chemical emergencies.
|
|
Country Work in Cancer Research and Cancer Control Planning Strengthening - Kenya
|
Other
|
CDC
|
NCI, FIC, NIAID
|
Kenya has an estimated population of over 42 million. Cancer ranks third as a cause of death after infectious and cardiovascular diseases. It estimated that over 18,000 Kenyans die of cancer annually. The most common types of cancer in Kenya are cancers of the cervix, breast, esophagus, and prostate. The Ministry of Health released a National Cancer Control Strategy (2010-2015) and a National Cervical Cancer Prevention Program Strategic Plan (2012-2015). NCI looks to build upon those efforts in coordination with the many US government and non-governmental partners (NGOs) working in the country. US government agencies, including the National Cancer Institute (NCI), the National Institute of Allergy and Infectious Disease (NIAID), the Fogarty International Center (FIC), the Centers for Disease Control (CDC), and the US Agency for International Development (USAID) have a significant presence in Kenya. Between FY2010 and FY2012, there were 121 NIH or CDC awards totaling $160.1M, and USAID invested $700 million in Kenya in FY2011. At least six NCI-designated cancer centers have activities in Kenya ranging from capacity building for cancer screening and treatment to studies of cancers associated with chronic infection, including HPV. Notably, Moi University has hosted the Academic Model Providing Access to Healthcare (AMPATH) partnership, along with Indiana University (IU), since 2001. The AMPATH-Moi-IU partnership has created the largest clinical research data enterprises in the developing world and includes 18 HIV clinics in western Kenya with 2,000 new patients enrolling per month as of 2012.
|
|
Covid Serology Research and Results Tracker (SeroHub)
|
Resource Development
|
CDC
|
NCI, NIAID
|
The Covid-19 Serology Research Tracking System and Dasboard serves as a research resource to the NCI/NIAID/CDC and to the broader research community to monitor seroprevalence.
|
|
COVID Special Interest Group (SIG)
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NIAID
|
Discuss epidemiology studies related to SARS-CoV-2 variants
|
|
COVID-19 Health and Safety Briefs
|
Training Initiative
|
CDC
|
NIEHS
|
A number of technical documents/briefs were created to provide guidance: Selection and Use of Portable Air Cleaners to Protect Workers from Exposure to SARS CoV-2; Key Information for Workplace and Training Provider; Respiratory Hazard Assessment Brief.
|
|
COVID-19 Open Data Portal
|
Research Initiative
|
ASPR
|
NCATS, NIAID, NLM
|
The NCATS OpenData COVID-19 portal is a resource designed to rapidly and openly share SARS-CoV-2 screening data and assay information with the global health community. NCATS scientists have been working to develop a number of SARS-CoV-2-related assays to measure over 10,000 compounds - including the NCATS Pharmaceutical Collection of nearly 3,000 approved drugs - for their activity against the virus. These data include all positive and negative results from a diverse panel of repurposing screens, and can be viewed, sorted, searched and exported directly from the portal website. Screening data are uploaded to the website as soon as they become available.This resource aims to reimagine the early translation process by sharing screening data immediately and without restrictions. We hope to enable a variety of drug repurposing activities and allow researchers to formulate and test hypotheses, prioritize research opportunities and speed the search for effective therapies against the virus and the disease it causes. In collaboration with ACTIV TRACE, OpenData Portal is now sharing curated in vitro therapeutic activity data on SARS-CoV-2 variants.
|
|
COVID-19 Scenario Modeling Hub (SMH)
|
Research Initiative
|
CDC
|
FIC, NIGMS
|
From weather to infectious diseases, it has been shown that synergizing results from multiple models gives more reliable projections than any one model alone. The COVID-19 Scenario Modeling Hub is a collaborative effort between multiple government agencies and academic institutions to harmonize COVID-19 projections in the United States and facilitate planning and decision making at a 3-12 month time scale.;Since December 2020, the COVID19 scenario modeling hub has released 12 rounds of projections on issues as varied as the impact of the vaccination program, non-pharmaceutical interventions, waning immunity, and new variants on the trajectory of cases, hospitalizations and deaths across the US. The most recent set of projections addresses the impact of Omicron. In each round of projections, a set of 4 scenarios are identified to allow alignment of model projections for collective insights. Scenarios are designed in consultation with academic modeling teams, NIH and the CDC. Between 6 and 10 models have contributed to each round. All projections are made publicly available via the COVID-19 scenario modeling hub github and website. After each round, a report summarizing key results is shared with decision-makers and public health stakeholders. There has been substantial media coverage on this effort. This study builds on long-standing efforts led by the Fogarty International Center’s in-house research division to develop computational approaches to mitigate pandemic risk and foster collaborative network in disease modeling. This effort extends a prior collaboration titled the Multinational Influenza Seasonal Mortality Study (MISMS) to assess the epidemiology, ecology, and evolutionary dynamics of influenza and other rapidly transmissible respiratory viruses. Multinational and bilateral collaborations developed through MISMS collect, analyze, and disseminate research findings through scientific publications, training workshops, and communication tools for investigators and decision-makers. These research findings inform numerous national governments, multilateral organizations, and research stakeholders on interventions for both pandemic and seasonal influenza. To date, data have been acquired from more than 40 countries (representing ~3.2 billion people), resulting in over 220 publications.
|
|
COVID-19 Therapeutics Interagency Working Group
|
Committee, Work group, Advisory group, or Task Force
|
FDA, CDC
|
NIAID
|
To share updates on the wide range of COVID therapeutics efforts that are progressing across the agencies
|
|
CTAC Ad hoc Strategic Planning Working Group (CTAC SPWG)
|
Committee, Work group, Advisory group, or Task Force
|
FDA, CMS
|
NCI
|
The CTAC SPWG was charged to re-assess NCI’s strategic vision for its clinical trials system for 2030 and beyond. The Working Group will review and address the capabilities of the clinical trials infrastructure necessary for achieving this vision as well as consider recommendations for relevant future CTAC activities.
|
|
Cytokine Interest Group
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NCI, NEI, NHGRI, NIA, NIAID, NIAMS, NICHD, NIDCR, NIDCD
|
The Cytokine Interest Group brings together the National Institutes of Health (NIH) and Food and Drug Administration (FDA) scientists from many different areas working with cytokines as mediators of immune processes. It provides a platform for establishing networks for the exchange of ideas and reagents. Its activities comprise multiple minisymposia throughout the year and an award for the best paper in cytokine research for postdoctoral fellows working at the NIH or FDA.
|